Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vaginal bacterial mixture
- Development stage
- Unknown
- Lead developer
- Hadassah Medical Organization
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
The vaginal bacterial mixture is an investigational live biotherapeutic product consisting of a synthetic consortium of healthy, commensal vaginal bacteria (primarily *Lactobacillus* species). Developed by Dr. Ahinoam Lev-Sagie at the Hadassah Medical Organization in collaboration with the Weizmann Institute of Science, this artificial mixture is designed to restore a healthy, *Lactobacillus*-dominated vaginal microbiome in women suffering from recurrent bacterial vaginosis (BV). Administered vaginally following standard antibiotic therapy, the mixture aims to re-establish the natural acidic microenvironment of the vagina, outcompete dysbiotic anaerobic pathogens, and prevent the high rates of recurrence typically associated with antibiotic-only regimens.
- Other names
- artificial vaginal bacterial mixturemicrobial cocktailsynthetic bacterial consortia
Beyond the preview
Go deeper on vaginal bacterial mixture.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vaginal bacterial mixture.